Clinical Trials Directory

Trials / Terminated

TerminatedNCT01939691

Macular Edema Nepafenac vs. Difluprednate Uveitis Trial

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
9 (actual)
Sponsor
University of California, San Francisco · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Macular edema is a condition in which there is swelling in the macula, the part of the retina that gives you your best vision. This swelling can cause your vision to decline. When diagnosed early and treated, you vision usually can be preserved. However, if the swelling goes untreated for a long time, it can cause permanent vision loss. We think that the three eye drop regimens in this study, difluprednate, difluprednate plus nepafenac, and prednisolone acetate plus nepafenac, might be effective in treating uveitic macular edema. Patients who enter this study are randomized to one of the three regimens and followed for 24 weeks.

Detailed description

Trial: Randomized 3 arm (1:1:1) parallel design comparative effectiveness trial Stratification: Systemic corticosteroid/immunosuppressive therapy vs. none Treatments: 1) difluprednate 0.05% 2) combination therapy of prednisolone acetate 1% with nepafenac 0.1% 3) combination therapy of difluprednate 0.05% with nepafenac 0.1% Masking: Unmasked treatment administration; masked outcome assessment (evaluation of OCT and visual acuity) Follow-up: 2, 4, 6, 8, and 24 weeks Treatment protocol: Patients will be randomized at enrollment to either: * difluprednate 0.05% 4 drops per day * prednisolone acetate 1% 4 drops per day and nepafenac 0.1% 3 drops per day * difluprednate 0.05% 4 drops per day and nepafenac 0.1% 3 drops per day If macular edema has not resolved at Week 4, continue study treatment at the same dose until Week 6. If macular edema has resolved at Week 4, reduce study treatment as follows: * difluprednate 0.05% 1 drop per day until Week 6, then stop * prednisolone acetate 1% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 6, then stop * difluprednate 0.05% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 6, then stop If macular edema does not resolve at Week 4 but has resolved at Week 6, reduce study treatment at Week 6 as follows: * difluprednate 0.05% 1 drop per day until Week 8, then stop * prednisolone acetate 1% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 8, then stop * difluprednate 0.05% 1 drop per day and nepafenac 0.1% 3 drops per day until Week 8, then stop If macular edema resolves at Week 4 but reoccurs at Week 6, treat per best medical judgement. After Week 8, there are no restrictions on the treatments patients may receive, and medications can be tapered further, discontinued, or changed at the discretion of the treating physician and patient preference. If a patient with previously resolved macular edema has a recurrence, the physician may treat according to best medical judgement.

Conditions

Interventions

TypeNameDescription
DRUGDifluprednateDifluprednate 0.05% - corticosteroid eyedrop
DRUGNepafenacNepafenac 0.1% - NSAID eyedrop
DRUGPrednisolone acetateprednisolone acetate 1% - corticosteroid eyedrop

Timeline

Start date
2018-09-12
Primary completion
2020-03-31
Completion
2020-03-31
First posted
2013-09-11
Last updated
2021-01-13

Locations

3 sites across 1 country: India

Source: ClinicalTrials.gov record NCT01939691. Inclusion in this directory is not an endorsement.